Left Ventricular Ejection Fraction Assessment Among Patients With Acute Myocardial Infarction and Its Association With Hospital Quality of Care and Evidence-Based Therapy Use

Background—The left ventricular ejection fraction (LVEF) has prognostic and therapeutic utility after acute myocardial infarction (AMI). Although LVEF assessment is a key performance measure among AMI patients, contemporary rates of in-hospital assessment and its association with therapy use have not been well characterized. Methods and Results—We examined rates of in-hospital LVEF assessment among 77 982 non–ST-elevation myocardial infarction patients and 50 863 ST-elevation myocardial infarction patients in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines between January 2007 and September 2009, after excluding patients who died in-hospital or who were transferred to another acute care facility, discharged to end-of-life care, or had missing LVEF assessment status. LVEF assessment increased significantly over time, with higher rates among ST-elevation myocardial infarction than non–ST-elevation myocardial infarction patients (95.1% versus 91.6%; P<0.001). Excluding patients with prior heart failure did not alter these observations. Significant interhospital variability in LVEF assessment rates was observed. Compared with patients with in-hospital LVEF assessment, patients who did not have LVEF assessed were older and more likely to have clinical comorbidities. In multivariable modeling, lower overall hospital quality of AMI care was also associated with lower likelihood of LVEF assessment (odds ratio for failure to assess LVEF, 1.09; 95% confidence interval, 1.05–1.13 per 10% decrease in defect-free care). Patients with in-hospital LVEF assessment were more likely to be discharged on evidence-based secondary prevention medication therapies compared with paients without LVEF assessment. Conclusions—The assessment of LVEF among patients with AMI has improved significantly over time, yet significant interhospital variability exists. Patients who did not have in-hospital LVEF assessment were less likely to receive evidence-based medications at discharge. These patients represent targets for future quality improvement efforts.

[1]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[2]  A. Yan,et al.  Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. , 2010, American heart journal.

[3]  L. Schwamm,et al.  Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure. , 2009, American heart journal.

[4]  Li Liang,et al.  Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. , 2009, Journal of the American College of Cardiology.

[5]  J. Gore,et al.  Trends in the use of echocardiography and left ventriculography to assess left ventricular ejection fraction in patients hospitalized with acute myocardial infarction. , 2009, American heart journal.

[6]  C. Cannon,et al.  Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. , 2009, The American journal of cardiology.

[7]  C. Yancy,et al.  Influence of hospital length of stay for heart failure on quality of care. , 2008, The American journal of cardiology.

[8]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[9]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.

[10]  J. Gore,et al.  Changing trends in the evaluation of ejection fraction in patients hospitalized with acute myocardial infarction: the Worcester Heart Attack Study. , 2008, American heart journal.

[11]  Adnan Kastrati,et al.  Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. , 2007, Journal of the American College of Cardiology.

[12]  C. Yancy,et al.  Get with the guidelines steering committee and hospitals, sex and racial differences in the use of implantable cardioverter & defibrillators among patients hospitalized with heart failure , 2007 .

[13]  Harlan M Krumholz,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Journal of the American College of Cardiology.

[14]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[15]  S. Solomon,et al.  Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. , 2005, The New England journal of medicine.

[16]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[17]  V. Roger,et al.  Measurement of ejection fraction after myocardial infarction in the population. , 2004, Chest.

[18]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[19]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[20]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[21]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[22]  J. Vandenbossche,et al.  Predictors of early death after acute myocardial infarction: two months follow-up. , 1986, European heart journal.

[23]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[24]  K. Hammermeister,et al.  Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. , 1979, Circulation.

[25]  K. Hammermeister,et al.  Variables Predictive of Survival in Patients with Coronary Disease: Selection by Univariate and Multivariate Analyses from the Clinical, Electrocardiographic, Exercise, Arteriographic, and Quantitative Angiographic Evaluations , 1979 .

[26]  L. Fleisher,et al.  Writing Committee Members 3 , 2014 .

[27]  Jane A. Linderbaum,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Circulation.

[28]  W. Frishman Sudden Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both , 2006 .

[29]  R. Becker,et al.  Guidelines for the Management of Patients with Acute Myocardial Infarction , 2004, Journal of Thrombosis and Thrombolysis.

[30]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .